Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Sangamo Enters License Agreement With Genentech To Develop Intravenously Administered Genomic Medicines For Neurodegenerative Diseases; Co. Expected To Receive $50M In Near-Term Upfront License Fees And Is Eligible For Up To $1.9B In Milestones

Author: Benzinga Newsdesk | August 06, 2024 08:06am

Posted In: SGMO